VanEck Associates
VKTX icon

VanEck Associates’s Viking Therapeutics VKTX Stock Holding History

VanEck Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,911
Closed -$600K – 1410
2024
Q4 		$600K Buy
14,911
+5,475
+58% +$312K ﹤0.01% 1112
2024
Q3 		$570K Sell
9,436
-6,843
-42% -$401K ﹤0.01% 1074
2024
Q2 		$863K Buy
+16,279
New +$1.07M ﹤0.01% 1007

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VanEck Associates's VKTX Position: Q1 2025 in Review

VanEck Associates sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 14,911 shares — an estimated $600K sold.

VanEck Associates first reported a position in VKTX in Q2 2024 and held it in 3 quarters. The position peaked at $863K in Q2 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • VanEck Associates reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • VanEck Associates sold 14,911 Viking Therapeutics shares in Q1 2025, an estimated $600K.
  • VanEck Associates first reported a position in Viking Therapeutics in Q2 2024 and held it in 3 quarters.
  • VanEck Associates's Viking Therapeutics position peaked at $863K in Q2 2024.
  • 373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on VanEck Associates's 13F filing for Q1 2025, filed 15 May 2025.